Avikana completes registration and commercial export

2021-11-10 03:03:47 By : Mr. Eric Soonwell

September 16, 2021 07:30 ET | Source: Avianna Inc. Avianna Inc.

/ Not for distribution to American news agency services or dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws/

Toronto, September 16, 2021 (GLOBE NEWSWIRE) - Avianna Inc. ("Avianna" or "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a company focused on development , Manufacturing and commercialization of plant-derived cannabinoid products is pleased to announce that it has completed product registration and completed the first commercial export of Pura Earth brand skin cosmetic products in Ecuador.

The initial export includes four SKUs of Pura Earth brand products produced in Colombia under GMP conditions, and will be commercialized and distributed through retail and e-commerce channels in cooperation with Spenta SA. CBD skin cosmetics have also been registered and approved for sale as consumer products by Ecuador’s health authorities, Agencia Nacional de Regulación, Control y Vigilancia Sanitaria ("ARCSA").

The potential of Pura Earth and CBD skincare

Pura Earth product formulations have been developed and optimized to synergize with other natural ingredients known to provide specific functional benefits in skin care 1-2 to provide purified, THC-free cannabidiol ("CBD"). CBD has been shown to promote skin health by inducing antioxidant, anti-inflammatory and anti-apoptotic reactions, which may benefit various skin diseases such as eczema or atopic dermatitis1-3. In addition, CBD can down-regulate the activity of cells that are essential for skin oil production, so it may inhibit the production of acne-prone skin4.

Three (3) of the four (4) Pura Earth products are tested by dermatologists to ensure that skin irritation or allergies will not occur, they are proven to be physically and chemically stable, and each product has a shelf life of at least two (2 years. In the past three (3) years, the formula has been optimized through Avikana's R&D infrastructure to increase the absorption of CBD by the skin and meet the needs of various consumers. Except for the completed clinical trials, all Pura Earth products have not been tested on animals and are vegan.

"After years of research and development and clinical development of what we consider to be the most advanced CBD skin care product line, we are happy to expand our distribution capabilities to Ecuador. Although this is the early stage of the Latin American market, we believe this shows Pura Earth as the The potential of leading skincare brands in the region,” said Lucas Nosiglia, President of Avikana LATAM.

About the initial 3 Pura H&W products and clinical studies

Three cosmetic clinical studies were completed on Avikana's formulas, which target the beauty factors associated with aging, acne-prone skin, and eczema-prone skin. The successfully completed study involved 156 patients who were tested for safety and specific skin cosmetic endpoints, including hydration and hyperlipidemia. All three studies have achieved positive results in terms of endpoints and no adverse effects, making Pura Earth one of the only cannabis consumption series with human safety and effectiveness data. For more information, see the Clinicaltrials.gov registry.

References: 1. Tóth, KF, etc. (2019). Cannabinoid signals in the skin: the therapeutic potential of the "C(ut)annabinoid" system. Molecule (Basel, Switzerland), 24(5), 918. htt ps://doi.org/10.3390/molecules24050918

2. Baswan, SM, etc. (2020). Cannabidiol (CBD) has therapeutic potential for skin health and disease. Clinical, Aesthetic and Research Dermatology, 13, 927-942. htt ps://doi.org/10.2147/CCID.S286411

3. Atalay S et al. (2020). The antioxidant and anti-inflammatory properties of cannabidiol. Antioxidants. 9(1): 21.

4. Oláh, A., Tóth, B. etc. (2014). Cannabidiol has sebum-inhibiting and anti-inflammatory effects on human sebaceous gland cells. Journal of Clinical Research, 124(9), 3713-3724.

5. Herbal Products Committee (HMPC). (2013). Evaluation report of Melaleuca alterniflora (tea tree oil) and other Melaleuca species, aetheroleum. European Medicines Agency. Article 16d(1), Article 16f and Article 16h of Directive 2001/83/.

6. Carson, CF, Hammer, KA, & Riley, TV (2006). Melaleuca alterniflora (tea tree) oil: an overview of antibacterial and other medicinal properties. Clinical Microbiology Review, 19(1), 50-62.

7. Bassett IB et al. (1990). A comparative study of tea tree oil and benzoyl peroxide in the treatment of acne. Australian Journal of Medicine, 153: 455-458.

8. Andrade, JM, Faustino, C., et al, (2018). Rosmarinus officinalis L.: The latest reviews on its phytochemical and biological activities. Future Science OA, 4(4), FSO283.

9. Tsai, TH, Chuang, LT, et al, (2013). Rosemary extract inhibits the inflammatory response induced by P. acnes. Journal of Medicinal Food, 16(4), 324-333.

10. Reynertson, KA, Garay, M., Nebus, J., Chon, S., Kaur, S., Mahmood, K., Kizoulis, M., & Southall, MD (2015). The anti-inflammatory activity of colloidal oatmeal (Avena sativa) contributes to the effectiveness of oatmeal in treating itching associated with dry, irritated skin. Journal of Dermatological Drugs: JDD, 14(1), 43–48.

11. Horiba, H., etc. (2016). Biological activity of extracts from different parts of Cryptomeria fortunei. Natural Products Communications, 11(9), 1337-1342.

Avikana is a commercial-stage Canadian biopharmaceutical company and a recognized leader in cannabinoid research, development, and evidence-based products for global consumer, medical and pharmaceutical markets. Avikana conducts research in Canada, including its R&D headquarters in the Johnson & Johnson Innovation Center, JLABS @ Toronto, in the MaRS Discovery Zone, and cooperation with Canada's leading academic and medical institutions. Avikana has established an industry-leading scientific platform, including advanced R&D and clinical development, and has commercialized more than 20 products in four major market segments:

For more information about Pura Earth, please visit www.puraearth.com/es

For more information about Avicanna, please visit www.avicana.com, call 1-647-243-5283, or email iryna@chfir.com or call 416-868-1079 x 229 to contact IR representative Iryna Zheliasko.

The company publishes updates via videos from the company's official YouTube channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.

Notes on forward-looking information and statements

This press release contains "forward-looking information" in the sense of applicable securities laws. The forward-looking information contained in this press release can be identified by using words such as "may", "will", "may", "will", "may", "anticipate", "anticipate", "believe", etc. "Intend", "plan", "forecast", "project", "estimate", "forecast" and other similar expressions, and include statements about CBD's ability to promote skin health by inducing antioxidant and anti-inflammatory effects, as well as possible Eczema or atopic dermatitis is a beneficial anti-apoptotic response to many skin diseases. CBD can down-regulate the activity of cells that are essential for skin oil production, so it may inhibit the production in acne-prone skin. The company has the ability To ensure that Pura Earth products will not cause skin irritation or allergies, the company has the ability to continue to supply any Pura Earth products to the Ecuadorian market, and the company has the ability to continue to produce Pura Earth products and the leading skin care brand of Pura Earth being. Forward-looking information is not a guarantee of future performance, but is based on some estimates and assumptions made by management based on management’s experience and views on trends, current conditions and expected developments, and other relevant factors, including current and future market conditions , Current and future regulatory environment assumptions; and the availability of permits, approvals and permits.

Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, it should not rely excessively on forward-looking information because the company cannot guarantee that they will prove to be correct. Actual results and developments may differ materially from those envisaged in these statements. Forward-looking information is subject to various risks and uncertainties, which may cause actual events or results to be materially different from the events or results predicted in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions, including the market price of the company’s common stock, and the risk factors listed in the company’s annual information sheet and final summary dated September 3, 2021 The prospectus, dated November 27, 2020, has been submitted to the Canadian securities regulator and can be viewed in the company's profile on SEDAR at www.sedar.com.

The statements in this press release were made on the date of this press release. Except as required by applicable securities laws, the company does not undertake any intention or obligation to update any forward-looking information, whether due to new information, future events or results, or other reasons.